Protocol Ledger

NCT06456580 · Phase III · ACTIVE NOT RECRUITING

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Interventional Phase III clinical trial protocol NCT06456580 sponsored by Vor Biopharma in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-17 Enrollment: 191 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06456580
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)191 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06456580
Protocol FieldVerified Registry Value
NCT IdentifierNCT06456580
Consolidated Lead SponsorVor Biopharma
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment191 participants (ACTUAL)
Registered Start Date2024-07-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI